<DOC>
	<DOCNO>NCT00236743</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness oral topiramate add-on therapy child uncontrolled partial onset seizure take one two standard anti-epileptic drug .</brief_summary>
	<brief_title>A Study Effectiveness Safety Topiramate Treatment Children With Epilepsy</brief_title>
	<detailed_description>Epilepsy characterize seizure , abnormal electrical discharge brain temporarily disrupt normal brain function . Seizures classified `` generalize , '' originate side brain simultaneously , `` partial-onset , '' start one area brain . Antiepilepsy medication , topiramate , select base seizure type . This double-blind , placebo-controlled study include baseline phase treatment phase . During baseline phase ( 8 week duration ) , patient receive stable dose one two standard antiepileptic drug ( AEDs ) , parent guardian record occurrences seizure diary . Patients continue seizure treatment standard AEDs proceed double-blind treatment phase . Patients receive topiramate placebo daily dosage 25 milligram [ mg ] 50 mg base body weight ( 6mg/kg per day ) , increase gradually twice daily dose maximum 125-400 mg ( base body weight ) 112 day ( 16 week total duration double-blind phase ) , continue standard AED regimen . Assessments effectiveness include percent reduction average monthly seizure rate , percent patient respond treatment ( equal great 50 % reduction seizure rate ) , parent 's guardian 's global assessment medication end study . Safety assessment include incidence adverse event throughout study , clinical laboratory test ( hematology , chemistry , urinalysis ) , neurologic examination , vital sign measurement ( blood pressure , pulse , body weight ) specific interval treatment phase . The study hypothesis topiramate , take add-on therapy treatment AEDs , significantly reduce seizure frequency , compare placebo , child refractory partial epilepsy : , child continue seizures despite treatment first-line AEDs . In addition , hypothesize topiramate well-tolerated . Oral topiramate , daily 112 day . Starting dose 25 mg 50mg , base body weight . Maximum dos base patient weight : 125 mg/day ( 36-54 pound [ lb ] ) ; 175 mg/day ( 55-74 lb ) ; 225 mg/day ( 75-94 lb ) ; 400 mg/day ( 95 pound ) . Matching placebo use maintain blinding .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Patients must weigh least 36 pound ( 16 kilogram ) patient must partial onset seizure ( without secondarily generalize seizure ) treat least one , two antiepileptic drug ( AEDs ) patient must least 6 partial onset seizures 8week baseline phase , least one seizure 4week period electroencephalogram ( EEG ) feature consistent partial epilepsy perform prior study initiation baseline phase Females pregnant , nursing , use adequate birth control capable child patient treatable cause seizure ( example , infection ) patient progressive disorder nervous system patient clinical diagnosis LennoxGastaut syndrome patient history generalize status epilepticus ( repeat prolong seizure ) appropriate antiepileptic therapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>topiramate</keyword>
	<keyword>epilepsy</keyword>
	<keyword>partial epilepsy</keyword>
	<keyword>partial epilepsy</keyword>
	<keyword>seizure</keyword>
	<keyword>epileptic seizure</keyword>
	<keyword>partial seizure disorder</keyword>
	<keyword>child</keyword>
	<keyword>pediatric</keyword>
</DOC>